The PennZone

WEXFORD, Pa., Oct. 24, 2024 ~ Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has recently announced an expansion of its license agreement with Deverra Therapeutics Inc. This move will allow Coeptis to broaden the potential applications of its allogeneic natural killer (NK) cell technology in the treatment of viral infections, pandemic-related illnesses, and emergency stockpiling for future health crises.

The agreement, which was initially secured in August 2023, granted Coeptis exclusive rights to key assets from Deverra including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets align with Coeptis' mission to develop treatments for targeting cancer, autoimmune and infectious diseases.

With this revised agreement, Coeptis will now have the ability to expand its field of use in the event of pandemic-related and emergency situations. This includes utilizing unmodified NK cells as a treatment for illnesses and injuries arising from a pandemic or act of terror or war, such as Acute Radiation Sickness (ARS). It also allows for the production and storage of unmodified NK cells in advance to prepare for future health crises.

More on The PennZone

• IYKYK! Coffee Lab Thriving in Huntington Beach, Blending Elevated Coffee, Matcha, Music, and Community
• Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
• Sacred Surrogacy, CFC, and Egghelpers Launch Women's Retreats
• The Eichelberger Performing Arts Center Donates Theatrical Lights to Delone Catholic High School
• Moravian Academy Becomes First Pennsylvania School to Partner with Global Sustainability Institute

Dave Mehalick, President and CEO of Coeptis Therapeutics expressed his excitement about this expansion stating that it "broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic."

Coeptis Therapeutics Holdings, Inc., along with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Their goal is to disrupt conventional treatment paradigms and improve patient outcomes. The company's product portfolio includes assets licensed from Deverra Therapeutics, an allogeneic cellular immunotherapy platform, and DVX201, a clinical-stage unmodified natural killer cell therapy technology. They are also developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

More on The PennZone

• Stipenda Appoints David Epstein as Chief Operating Officer
• Woven Wire Mesh as a Durable Filter Medium for Industrial Filtration Systems
• FondoQuantaX Completes Core Trading Engine Upgrade: Refactoring High-Concurrency Architecture with AI Adaptive Algorithms to Navigate Market Extremes
• As Paris Hilton Reclaims Her Icon Status, "Pretty Pop Star" Reemerges to Battle the Age of AI Music
• Food Journal Magazine Is Shaping the Conversation Around Los Angeles Food in 2026

Coeptis' business model is centered around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. Their focus is on expanding their product rights and offerings, particularly in the areas of cancer and infectious diseases. The company is headquartered in Wexford, PA.

It is important to note that this news release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts, and assumptions that may cause actual results to differ materially from those projected. Coeptis urges readers to carefully review all cautionary statements regarding these forward-looking statements before making any investment decisions.

For more information on Coeptis Therapeutics Holdings, Inc., please visit their website at https://coeptistx.com/.

---

Show All News | Report Violation